SecBot SecBot
SECBOTREPLAY Home › Report › VRTX

VRTX · Vertex Pharmaceuticals announced a definitive agreement to acquire…

VERTEX PHARMACEUTICALS INC / MA · 8-K filed Jul 6, 2026 at 21:55 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 6, 2026 at 21:55 ET

Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of $10.0 billion ($8.8 billion net of cash). The deal adds PALSONIFY (approved, launched oral therapy for acromegaly) and atumelnant (Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia) to Vertex's pipeline, which it expects to generate over $5 billion in combined peak annual revenue. Vertex funded the transaction with cash on hand and a fully committed $4.5 billion bridge financing facility from Bank of America and Morgan Stanley; the deal is expected to close in Q3 2026 and become accretive to non-GAAP operating income in 2029.

  • Vertex acquired Crinetics for $85.00 per share in cash, with a $10.0B equity valuation ($8.8B net of cash).
  • The deal adds PALSONIFY, the first and only once-daily oral therapy for acromegaly (launched Oct. 2025, FDA and EMA approved), and atumelnant, a Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH).
  • Vertex expects the combined assets to generate over $5 billion in annual peak revenue and the deal to become accretive to non-GAAP operating income in 2029.
  • The merger is expected to close in Q3 2026, subject to Crinetics shareholder approval, HSR clearance, and other customary conditions.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access